Photo from academic.microsoft.com
Immune checkpoint therapy is beneficial for patients with advanced bladder cancer; however, trials generally exclude patients with comorbidities or uncommon histologies. The SAUL trial demonstrates that atezolizumab is safe and… Click to show full abstract
Immune checkpoint therapy is beneficial for patients with advanced bladder cancer; however, trials generally exclude patients with comorbidities or uncommon histologies. The SAUL trial demonstrates that atezolizumab is safe and efficacious in a patient population that more accurately reflects the real-world scenario, but its benefit might still be limited in historically poorly performing populations.
Keywords:
bladder cancer;
populations bladder;
understudied populations;
bladder;
atezolizumab understudied
Journal Title: Nature Reviews Urology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Urology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!